Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + mFOLFOX6 + cobimetinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
atrox_description **atezolizumab + mFOLFOX6 + cobimetinib** is a multi-agent combination regimen used in oncology clinical trials, primarily targeting advanced or metastatic colorectal cancer and other gastrointestinal cancers. - **Atezolizumab** is a monoclonal antibody checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), thereby enhancing antitumor immune response. - **mFOLFOX6** is a modified FOLFOX6 chemotherapy regimen containing oxaliplatin (a platinum-based DNA crosslinking agent), leucovorin (folinic acid, a biomodulator potentiated by the efficacy of fluorouracil), and fluorouracil (5-FU, an antimetabolite inhibiting thymidylate synthase and disrupting DNA synthesis)[1][2][5][6]. - **Cobimetinib** is a selective inhibitor of MEK1/2, blocking MAPK/ERK signaling crucial for cell proliferation. This regimen combines immune checkpoint blockade, cytotoxic chemotherapy, and targeted kinase inhibition for synergistic antitumor effect.
- Other names
- atezolizumab + mFOLFOX6 + cobimetinib
02
Targets
TS (Thymidylate synthase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)CD274 (Programmed cell death protein 1 ligand 1)DNAMEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on atezolizumab + mFOLFOX6 + cobimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + mFOLFOX6 + cobimetinib.